XML 35 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 10 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Operating activities            
Net loss $ (5,480,000) $ (46,459,000)   $ (88,424,000) $ (47,519,000) $ (178,594,000)
Adjustments to reconcile net loss to net cash used for operating activities:            
Depreciation and amortization 2,926,000 2,832,000   3,779,000 3,777,000 3,750,000
Amortization of debt issuance costs and debt discount 3,108,000 5,904,000   7,909,000 10,664,000 15,033,000
Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount (21,190,000) (11,813,000)   (12,487,000) (10,866,000) 0
(Gain) loss on debt extinguishment, net (28,634,000) 12,463,000   12,463,000 0 0
Non-cash operating lease cost 351,000 276,000   372,000 825,000 528,000
Stock-based compensation 4,027,000 4,368,000   5,822,000 5,395,000 4,330,000
Gain on derivative liability (5,300,000) (100,000)   300,000 (800,000) 23,300,000
Scilex Pharma Notes principal increase       28,000,000 0 0
Semnur-related IPR&D       0 0 75,301,000
Changes in operating assets and liabilities:            
Inventory 1,629,000 186,000   (1,417,000) 2,379,000 (1,116,000)
Accounts receivables, net (3,206,000) 517,000   (1,142,000) (598,000) (12,356,000)
Prepaid expenses and other (3,478,000) (1,647,000)   1,479,000 (1,035,000) (1,307,000)
Long-term deposits 385,000 0   0 2,580,000 (88,000)
Accounts payable 2,967,000 (2,784,000)   (3,836,000) (4,062,000) 4,271,000
Increase (Decrease) in Employee Related Liabilities (2,307,000) 360,000   (21,000) 1,247,000 1,131,000
Accrued expenses 12,403,000 (522,000)   409,000 2,051,000 3,689,000
Increase (Decrease) in Other Current Liabilities (255,000) (53,000)   (80,000) (604,000) (147,000)
Related party payable 21,521,000 13,765,000   18,210,000 5,105,000 1,854,000
Net cash used for operating activities (20,533,000) (22,707,000)   (28,664,000) (31,461,000) (60,421,000)
Investing activities            
Purchase of property, plant, and equipment (7,000)     0 (25,000) (584,000)
Acquisition consideration paid in cash for Romeg intangible asset acquisition (2,060,000) 0        
Acquisition of Semnur, net of cash acquired       0 0 (17,040,000)
Net cash used for investing activities (2,067,000) 0     (25,000) (17,624,000)
Financing activities            
Repayment of principal on the Scilex Pharma Notes (84,808,000) (32,376,000)   (33,387,000) (58,927,000) (2,334,000)
Repayment on other loans (18,800,000) (36,900,000)   (48,832,000) 0 0
Proceeds from other loans 9,857,000 34,799,000   47,832,000 11,007,000 0
Proceeds from stock options exercised 96,000     0 50,000 0
Proceeds from related party payable 51,900,000 45,050,000   47,850,000 18,400,000 0
Proceeds from related party note payable 62,500,000 11,500,000   14,700,000 10,300,000 21,628,000
Repayment of related party note payable       0 0 (3,518,000)
Net cash provided by financing activities 20,745,000 22,073,000   28,163,000 (19,170,000) 15,776,000
Net change in cash and cash equivalents (1,855,000) (634,000)   (501,000) (50,656,000) (62,269,000)
Cash and cash equivalents at beginning of period 4,338,000 4,839,000   4,839,000 55,495,000 117,764,000
Cash and cash equivalents at end of period 2,483,000 4,205,000 $ 4,839,000 4,338,000 4,839,000 55,495,000
Supplemental disclosures of non-cash investing and financing activities            
Deferred consideration for Romeg intangible asset acquisition 3,650,000 0        
Non-cash consideration in Semnur acquisition 0 409,000   409,000 0 54,591,000
Other loan forgiveness 0 1,536,000   1,536,000 0 0
Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount 4,162,000 0        
Fair value adjustment to derivative liability in troubled debt restructuring 30,400,000 0        
Live Action right-of-use asset in Palo Alto 320,000 0        
Semnur acquisition costs incurred but not paid in accounts payable       0 0 601,000
Non-cash distribution to Sorrento       0 9,600,000 5,800,000
Scilex Pharma Notes principal increase       28,000,000 0 0
Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet            
Cash and cash equivalents 2,483,000   4,839,000 4,338,000 4,839,000 10,295,000
Restricted cash     0 0 0 $ 45,200,000
Vickers Vantage [Member]            
Operating activities            
Net loss 623,516 (349,248) (6,276) 783,438    
Adjustments to reconcile net loss to net cash used for operating activities:            
Formation cost paid through advances from affiliate of Sponsor     5,000    
Amortization of debt issuance costs and debt discount 0     16,901    
Income earned on investments held in Trust Account (664,973) (28,006) (30,739)    
Interest on mandatorily redeemable ordinary shares liability (192,049) 0        
Change in fair value of warrant liability (2,188,800) (2,872,800) (4,377,600)    
Loss on initial issuance of private warrants 0 2,599,200 2,599,200    
Change in fair value of conversion option liability (6,892) 0 (11,835)    
Amortization of debt discount 16,901 0 1,826    
Transaction costs allocated to warrant liabilities 0 30,212 30,212    
Changes in operating assets and liabilities:            
Prepaid expenses (126,252) (116,536) (4,536)    
Accounts payable and accrued expenses 600,588 43,569 208,704    
Net cash used for operating activities (1,937,961) (693,609) (1,276) (801,330)    
Investing activities            
Investment of cash in Trust Account (3,041,666) (139,380,000) (139,380,000)    
Cash withdrawn from Trust Account in connection with redemption 41,824,292 0        
Net cash used for investing activities 38,782,626 (139,380,000) (139,380,000)    
Financing activities            
Proceeds from other loans 1,535,000 0 500,000    
Proceeds from related party payable 0 25,000 25,000 25,000    
Proceeds from sale of Units, net of underwriting discounts paid 0 135,600,000 135,600,000    
Proceeds from sale of Private Placement Warrants 0 5,130,000 5,130,000    
Repayment of advances from related party 0 (55,000) (55,000)    
Proceeds from simple promissory note – related party 2,971,667 0        
Repayment of promissory note – related party 0 (125,000)        
Proceeds from promissory note – related party     125,000    
Repayment of promissory note – related party     (125,000)    
Payment of offering costs 0 (416,260) (118,213) (416,260)    
Redemption of ordinary shares (41,824,292) 0        
Net cash provided by financing activities (37,317,625) 140,158,740 31,787 140,658,740    
Net change in cash and cash equivalents (472,960) 85,131 30,511 477,410    
Cash and cash equivalents at beginning of period 507,921 30,511 0 30,511    
Cash and cash equivalents at end of period 34,961 115,642 30,511 507,921 $ 30,511  
Supplemental disclosures of non-cash investing and financing activities            
Deferred underwriting fee payable $ 0 $ 5,190,000 5,190,000    
Offering costs included in accrued offering costs     25,760    
Offering costs paid through promissory note – related party     $ 25,000